|
Market Closed -
Australian S.E.
02:10:10 2026-09-25 EDT
|
5-day change | 1st Jan Change | ||
| 0.0360 AUD | -5.26% |
|
-5.26% | -91.33% |
| 09-16 | Immutep refocuses efti development on head and neck cancer and soft tissue sarcoma | FI |
| 09-15 | Immutep's Drug Candidate Now Has Clearer Potential Development Path, Jefferies Says | MT |
Company Valuation: Immutep Limited
Data adjusted to current consolidation scope
| Fiscal Period: June | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 247.7 | 374 | 420.2 | 350.5 | 78.11 | 56 | - | - |
| Change | - | 50.99% | 12.36% | -16.6% | -77.72% | -28.3% | - | - |
| Enterprise Value (EV) 1 | 169.2 | 251.4 | 259.4 | 284.2 | 14.43 | 1.401 | 22.17 | -3.665 |
| Change | - | 48.63% | 3.18% | 9.55% | -94.92% | -90.29% | 1,481.84% | -116.53% |
| P/E | -7.65x | -7.05x | -8.29x | -5.69x | -0.98x | -2.24x | -3.45x | -5.18x |
| PBR | 2.62x | 2.74x | 2.26x | 2.43x | 1.27x | 3.04x | 6.33x | 0.77x |
| PEG | - | -0.4x | 0.4x | -0.3x | -0x | 0x | 0.1x | 0.2x |
| Capitalization / Revenue | 36.7x | 71.9x | 53.6x | 33.9x | 3.23x | 14x | 18.7x | 28x |
| EV / Revenue | 25x | 48.3x | 33.1x | 27.5x | 0.6x | 0.35x | 7.39x | -1.83x |
| EV / EBITDA | -5.63x | -6.65x | -6.42x | -4.82x | -0.19x | -0.05x | -1.01x | 0.22x |
| EV / EBIT | -5.27x | -6.31x | -6.08x | -4.63x | -0.18x | -0.05x | -0.61x | 0.1x |
| EV / FCF | -5.59x | -7.09x | 7.46x | -4.58x | -0.26x | -0.06x | -1.03x | 0.27x |
| FCF Yield | -17.9% | -14.1% | 13.4% | -21.8% | -385% | -1,784% | -97% | 368% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.0379 | -0.0447 | -0.0356 | -0.0422 | -0.0539 | -0.017 | -0.011 | -0.00733 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 6.758 | 5.2 | 7.839 | 10.33 | 24.17 | 4 | 3 | 2 |
| EBITDA 1 | -30.05 | -37.81 | -40.42 | -59.01 | -76.76 | -27.67 | -22.03 | -17.03 |
| EBIT 1 | -32.12 | -39.88 | -42.69 | -61.4 | -79.24 | -29.6 | -36.27 | -36.36 |
| Net income 1 | -32.21 | -39.9 | -42.72 | -61.43 | -79.3 | -26.1 | -30.47 | -31.07 |
| Net Debt 1 | -78.54 | -122.6 | -160.8 | -66.3 | -63.67 | -54.6 | -33.83 | -59.67 |
| Reference price 2 | 0.2900 | 0.3150 | 0.2950 | 0.2400 | 0.0530 | 0.0380 | 0.0380 | 0.0380 |
| Nbr of stocks (in thousands) | 854,123 | 1,187,306 | 1,424,548 | 1,460,390 | 1,473,721 | 1,473,721 | - | - |
| Announcement Date | 8/31/22 | 8/29/23 | 8/29/24 | 8/28/25 | 8/30/26 | - | - | - |
1AUD in Million2AUD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.24x | 0.35x | -0.05x | - | 39.28M | |
| 33.31x | 5.98x | 17.9x | 0.97% | 48.01B | |
| 35.42x | 3.39x | 14.64x | -.--% | 45.27B | |
| 47.15x | 5.46x | 29.88x | -.--% | 40.93B | |
| -20.54x | 221.64x | -22.17x | -.--% | 42.84B | |
| 26.85x | 7.74x | 19.93x | 0.42% | 29.6B | |
| 35.29x | 5.79x | 26.32x | -.--% | 17.32B | |
| 25.91x | 2.22x | 9.63x | 1.03% | 15.34B | |
| -59.05x | 9.67x | 236.13x | -.--% | 14.84B | |
| Average | 13.57x | 29.14x | 36.91x | 0.3% | 28.24B | |
| Weighted average by Cap. | 20.38x | 41.96x | 25.54x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- IMM Stock
- Valuation Immutep Limited
Select your edition
All financial news and data tailored to specific country editions
